PATENT CLAIM ANALYSIS

Application Number: 16118991
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "217000"]

Abstract:
Tricyclic compounds, including tricyclic iminodibenzylic and tricyclic iminostilbene compounds, are identified as therapeutic agents for inhibition of delta-5-desaturase (D5D) and for treating or preventing cancer and precancerous conditions, as well as autoimmune and inflammatory conditions. Pharmaceutical compositions and dietary supplements are provided, as are methods of administration and treatment.

Claim (Index 14):
A pharmaceutical composition comprising:\n an active agent comprising a compound according to  claim 1 ; and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 96.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13051790', '13940907', '13993317', '15745603', '12790533']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6974717075497059
- 35 USC 102 Novelty (BERT): 0.478479986750735
- Combined Prediction Score: 0.6755725354698088
- Mean Citation Score: 168.66561399999995
- Max Citation Score: 174.65732
- Similarity Product: 134.9700911635208

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test